First-line therapy in ovarian cancer trials

International Journal of Gynecological Cancer

Volumn 21, Issue 4, 2011, Pages 756-762

  Thigpen, Tate ^a   DuBois, Andreas ^a   McAlpine, Jessica ^a   DiSaia, Philip ^a   Fujiwara, Keiichi ^a   Hoskins, William ^b   Kristensen, Gunnar ^a   Mannel, Robert ^a   Markman, Maurie ^a   Pfisterer, Jacobus ^a   Quinn, Michael ^a   Reed, Nick ^a   MarieSwart, Ann ^c   Berek, Jonathan ^a   Colombo, Nicoletta ^a   Freyer, Gilles ^a   Gallardo, Dolores ^a   Plante, Marie ^a   Poveda, Andres ^a   Rubinstein, Lawrence ^b   Bacon, Monica ^a   Kitchener, Henry ^c   Stuart, Gavin C E ^a   more..

^a GOG ^*  (Spain)

^b NCI   (United States)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Clinical trials; First line therapy; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; PACLITAXEL; PLACEBO;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CONSENSUS DEVELOPMENT; HEALTH CARE COST; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CLINICAL TRIALS AS TOPIC; CONSENSUS; ENDPOINT DETERMINATION; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 80051888617     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821ce75d     Document Type: Conference Paper

References (25)

1. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322. (Pubitemid 32642183)
2. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16:3345-3352. (Pubitemid 28481631)
3. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 1996;63:89-93. (Pubitemid 26337972)
4. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:405-410. (Pubitemid 28135580)
5. Markman M, Blessing J, Rubin SC, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:436-440. (Pubitemid 43729968)
6. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:130-135. (Pubitemid 36263370)
7. Bajetta E, Di Leo A, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1996;14:2546-2551. (Pubitemid 26300122)
8. Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1992;10:243-248.
9. Look KY, Muss HB, Blessing JA, et al. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol. 1995;18:19-22.
10. Markman M, Blessing JA, Moore D, et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 1998;69:226-229. (Pubitemid 28289964)
11. Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009;27:2686-2691.
12. Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. J Clin Oncol. 2009;27:3097-3103.
13. Kavanagh JJ, Sill MW, Ramirez PT, et al. Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2008;18:460-464. (Pubitemid 351668320)
14. Vergote IB, Micha JP, Pippitt CH Jr, et al. Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer [abstract]. J Clin Oncol. 2010;28:393s.
15. Naumann RW, Symanowski JT, Ghamande SA, et al. PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin in combination versus PLD alone in subjects with platinum-resistant ovarian cancer [abstract]. J Clin Oncol. 2010;28:952s.
16. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:5165-5171. (Pubitemid 350237599)
17. Markman M, Iseminger KA, Hatch KD, et al. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol Oncol. 1996;62:4-6. (Pubitemid 26234538)
18. Matei D, Sill MW, DeGeest K, et al. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study [abstract]. J Clin Oncol. 2008;26:301s.
19. Behbakht K, Sill MW, Darcy KM, et al. Phase II trial of the mTOR inhibitor temsirolimus and evaluation of circulating tumor cells in persistent or recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study [abstract]. Gynecol Oncol. 2010;116:S5.
20. Matulonis UA, Berlin S, Ivy P et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27:5601-5606.
21. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor oaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376:235-244.
22. Omura G, Blessing J, Ehrlich C, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer. 1986;57:1725-1730. (Pubitemid 16111979)
23. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2000;18:106-115. (Pubitemid 30036343)
24. Brady M. First-line therapy in ovarian cancer surrogate endpoints for accelerated approval. Available at: http:// www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/ DevelopmentResources/CancerDrugs/ucm094640.pdf.
25. Buyse M. Is PFS a ''valid''surrogate for OS in advanced ovarian cancer? A meta-analysis. Available at: http://www.fda.gov/ downloads/Drugs/ DevelopmentApprovalProcess/ DevelopmentResources/CancerDrugs/ucm094610.pdf.